Ratings Surperformance

Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
-

Ratings ESG MSCI

Ratings IRLAB Therapeutics AB: Strengths and Weaknesses

Highlights: IRLAB Therapeutics AB
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses: IRLAB Therapeutics AB
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.

Rating Financials

IRLAB Therapeutics AB SectorSweden

Fundamentals

-

Growth

-

Revenue growth

EPS growth

-

FCF growth

-

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

-
More ratings

Rating Valuation

IRLAB Therapeutics AB SectorSweden

Global Valuation

-

Enterprise Value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

-
More ratings

Rating Consensus

IRLAB Therapeutics AB SectorSweden

Consensus

-

Analysts' buy/sell recommendations

-

Analysts' recommendations evolution (1 year)

-

Analysts' recommendations evolution (4 months)

-

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

-

Target Price evolution (7 days)

More ratings

Rating Business Predictability

IRLAB Therapeutics AB SectorSweden

Visibility

-

Analysts' coverage

Financial estimates divergence

-

Analysts' recommendations divergence

-

Analysts' Target price divergence

-

Surprise rates

Rating Revisions

IRLAB Therapeutics AB SectorSweden

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
10.48M - - - - - -
1,097B
A
622B
BBB
449B
AA
-
334B
AA
294B
A
286B
AAA
213B
A
195B
A
157B
AA
Average 364.67B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. IRLAB A Stock
  4. Ratings IRLAB Therapeutics AB